Shares of Abraxis Bioscience were up 30.49% to $52.00 a share on Wednesday after the company announced positive Phase III clinical results for for its lung cancer drug Abraxane. Abraxis's Abraxane is currently available as a breast cancer treatment.
Abraxis (ABII) stock price closed at $52.40 in after hours trading. ABII hit a 52 week high of $57.60 a share on April 22, 2009.
